(a) Basal, aIgM induced and aIgM+H2O2 induced phosphorylation of key nodal signaling proteins in WM (red) and Healthy Donor B-cells (black), (b) Principal component analysis of the generated phosphosignatures distinguishes WM from Healthy Donor B-cells, (c) Hierarchial clustering analysis distinguishes patient subsets with distinct BCR-phosphosignatures, (d) Ibrutinib trial: Representative change in basal levels of phosphorylation for 3 phosphoproteins on 6 months and 12 months of treatment (normalized to the pretreatment baseline), (e) WM subset analysis based on CD20 expression shows interclonal differential signaling (here LYN activation is shown in a representative WM sample).